Fig. 1
REG1CP is upregulated in CRC cells and its high expression is associated with poor patient outcome. a Quantitation of REG1CP, CCAT1 and CCAL in LCM colon cancer cells and paired normal colon epithelial cells using qPCR. n = 5 paired biologically independent samples. b, c Quantitation of REG1CP expression in FFPE CRC tissues and paired normal mucosa. n = 49 (b) or n = 101 (c) paired biologically independent samples. d REG1CP was expressed at higher levels in FFPE colon cancers compared with normal colon tissues as shown in ISH. n = 20 paired biologically independent samples. Scale bar, 100 μm. Dihydrodipicolinate reductase (DapB) as a negative control and RNA, U6 Small Nuclear 1 (U6) as a positive control. e Quantitation of REG1CP expression according to results shown in (d). n = 20 paired biologically independent samples. RS, reactivation score. f Comparison of REG1CP expression between CRCs and normal colon tissues in the published datasets acquired from R2. g Absolute quantitation of REG1CP in the cell lines using ddPCR. n = 3 independent experiments. h Quantitation of REG1CP in FFPE colon adenoma, normal colon mucosa and colon cancer tissues. i Comparison of REG1CP expression between colon adenoma, normal colon mucosa and colon cancer tissues in a published dataset acquired from R2. j Kaplan–Meier analysis of the probability of PFS of CRC patients in cohort 1 (left) and cohort 2 (right) after surgical excision using the high quartile of REG1CP levels as the cut-off. k Kaplan–Meier analysis of the probability of PFS of CRC patients in a published dataset acquired from the TCGA using the high quartile of REG1CP levels as the cut-off. n = 3 independent experiments. Data are presented as the Mean ± SEM (a, e, f, g, i), the Mean (b, c, h) or representatives (d). Statistical significance was calculated using a two-tailed t-test.
